Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments. <\/p>\n
Dr. Michael J. Pellini, chief executive of Foundation, told CNBC on Monday the deal can accelerate a move into precision medicine for oncology. <\/p>\n
\"It's an important day for patients battling cancer,\" he said in a \"Squawk Box\" interview, noting that Foundation helps doctors understand cancer at its blueprint and then deploy targeted therapeutics. <\/p>\n
Roche will pay $50 a share, or about $780 million, a premium of 109 percent to Foundation's closing price Friday. Roche will also invest $250 million in Foundation by acquiring newly issued shares. <\/p>\n
As a result, Roche will own 52.4 percent to 56.3 percent of Foundation. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.<\/p>\n
Reuters contributed to this report. <\/p>\n
<\/p>\n
Read the original here:<\/p>\n
Drug deal to target cancer: CEO<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Roche Holding has agreed to buy a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, in a move to bolster the Swiss drugmaker's personalized cancer treatments. Continue reading